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Abstract 
 
Aims: Sphingosylphosphorylcholine (SPC) elicits vasoconstriction at micromolar 
concentrations. At lower concentrations (1 μmol/l) however it does not constrict 
intrapulmonary arteries (IPA), but strongly potentiates vasoreactivity. Our aim was to 
determine whether this also occurs in a systemic artery and to delineate the signalling 
pathway.  
Methods and results: Rat mesenteric arteries and IPA mounted on a myograph were 
challenged with ~25 mmol/l [K
+] to induce a small vasoconstriction. SPC (1 μmol/l) 
dramatically potentiated this constriction in all arteries by ~400%. The potentiation was 
greatly suppressed or abolished by inhibition of PLC (U73122), PKC (inhibitory peptide), 
Src (PP2), and NADPH oxidase (VAS2870), and by Tempol (superoxide scavenger), but not 
by inhibition of  Rho kinase (Y27632). Potentiation was lost in mesenteric arteries from 
p47
phox -/-
  but not NOX2
-/-
 mice. The intracellular superoxide generator LY83583 mimicked 
the effect of SPC. SPC elevated reactive oxygen species (ROS) in vascular smooth muscle 
cells, and this was blocked by PP2, VAS2870 and siRNA knockdown of PKC. SPC (1 
μmol/l) significantly reduced the EC50 for U46619-induced vasoconstriction, an action 
ablated by Tempol. In patch-clamped mesenteric artery cells SPC (200 nmol/l) enhanced 
Ba
2+
 current through L-type Ca
2+
 channels, an action abolished by Tempol but mimicked by 
LY83583.  
Conclusion: Our results suggest that low concentrations of SPC activate a PLC-coupled  and 
NOX1-mediated increase in ROS, with consequent enhancement of voltage-gated Ca
2+
 entry 
and thus vasoreactivity. We speculate that this pathway is not specific for SPC, but may also 
contribute to vasoconstriction elicited by other GPCR and PLC-coupled agonists.    
  
 
Key words: NADPH oxidase, vascular smooth muscle, L-type Ca
2+
 channels, Protein kinase 
C epsilon, reactive oxygen species 
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Introduction  
Sphingosylphosphorylcholine (SPC) is derived from membrane sphingomyelin and is present 
in the plasma in sub-micromolar free concentrations and as a major component of low and 
high density lipoproteins; it is also released from activated platelets 
1-3
. Sphingolipids 
including SPC and sphingosine-1-phosphate (S1P) have been associated with cardiovascular 
disease, but whereas S1P has been extensively investigated and its receptors cloned, no 
specific receptor for SPC has been positively identified and there are no selective 
pharmacological antagonists. The actions of SPC are however stereospecific and dependent 
on phospholipase C (PLC), suggesting they are mediated via a G-protein coupled receptor 
(GPCR) 
1,4,5
.   
SPC induces vasoconstriction in isolated arteries via activation of Ca
2+
 entry and Rho kinase-
mediated Ca
2+
-sensitization, with an EC50 of ~12 μmol/l 
1,5-9
. However, plasma 
concentrations are at least 10-fold less than this, raising questions concerning the 
physiological relevance of vasoconstriction induced by SPC. Conversely, we have 
demonstrated in rat intrapulmonary arteries (IPA) that although low concentrations (1 μmol/l 
or less) of SPC do not on their own elicit vasoconstriction, cause depolarisation, elevate 
[Ca
2+
]i or activate Rho kinase, they strongly potentiate vasoreactivity by enhancing Ca
2+
 
entry induced by other stimuli 
10
. Although this effect was also stereospecific and dependent 
on PLC 
10
, it therefore clearly differs from the mechanisms previously shown to underlie 
vasoconstriction induced by higher concentrations of SPC. This implies an additional and 
hitherto unrecognised high affinity signalling pathway that could be of physiological 
relevance.     
SPC has been reported to induce generation of reactive oxygen species (ROS) in a variety of 
non-muscle cell types, probably via NADPH oxidase (NOX) 
11-14
, and ROS have been shown 
to enhance Ca
2+
 entry through L-type voltage-gated Ca
2+
 channels in vascular smooth muscle 
and cardiac myocytes 
15-18
. ROS have also been implicated in signalling pathways initiated by 
other PLC-coupled vasoconstrictor agonists, including angiotensin II and endothelin 
16,17,19
. 
This led us to hypothesise that a NOX/ROS-mediated pathway might underlie the SPC-
induced enhancement of IPA vasoreactivity. As the pulmonary vasculature exhibits some 
unique responses to changes in redox state and ROS 
20,21
, we focussed here on mesenteric 
artery (MA) to determine whether our previous observations were specific to the pulmonary 
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vasculature. We show that low, sub-contractile concentrations of SPC potentiate 
vasoreactivity of both MA and IPA through the same pathway, which involves PLC and 
PKC dependent activation of NOX1, increased production of ROS, and consequent 
enhancement of Ca
2+
 entry via L-type channels.  
 
METHODS 
Animals and tissues 
The study conforms with UK Home Office regulations and Directive 2010/63/EU of the 
European Parliament. Adult male Wistar rats were killed by lethal overdose of pentobarbital 
(i.p.). The lungs, mesentery and in some cases sections of small renal or main femoral artery 
were excised and placed in cold physiological saline solution (PSS; in mmol/l: 118 NaCl, 24 
NaHCO3, 1 MgSO4, 0.44 NaH2PO4, 4 KCl, 5.5 glucose, and 1.8 CaCl2). Male mice (6-8 
weeks old) lacking genes for gp91
phox
 
22
 (NOX2) and p47
phox
 
23
 (background for both 
C57BL/6) and PKC (background 129/SV) 24 or matched WT were killed by a Home Office 
approved method, the mesentery removed and placed in cold PSS.  
Small intrapulmonary (IPA), mesenteric (MA) or renal arteries (200–500 µm i.d.), or femoral 
artery segments (1-2 mm i.d.), were dissected free of connective tissue, mounted on a 
myograph (Danish Myo Technology, Denmark) and bathed in PSS gassed with 5% CO2, 
balance air (pH 7.4) at 37C. Vessels were stretched to equivalent transmural pressures of ~25 
(IPA) or ~90 mmHg (MA, renal), and pre-conditioned by repeated exposure to 80 mmol/l K
+
 
PSS (KPSS, equimolar substitution for NaCl) as previously described 
10,20
. Experiments were 
performed after ~30 min to allow for stabilization. Tension was recorded using Acquisition 
Engine software (Cairn Research Ltd, Faversham, UK). 
Cell culture, siRNA design and cell transfection 
Pulmonary artery smooth muscle cells (PASMCs) were dispersed from IPA using 
collagenase (type XI, 2mg/ml) and papain (1mg/ml), and cultured in DMEM containing 10% 
FCS as previously described 
10
. PASMCs from passages 3-4 were growth-arrested in serum-
free medium for 24 hr before use; each cell line was verified as smooth muscle by 
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immunostaining for smooth muscle α-actin, calponin and desmin (Sigma/Aldrich, Poole, 
UK). 
siRNAs were designed as described previously 
25
. The 19 nucleotide target sequences 
(PKC-siRNA: position 883–901, GenBank accession no. BC076505; PKCε-siRNA: position 
2079–2097, GenBank accession no. AY642593) were synthesized into 64–65 mer 
oligonucleotides with BamHI/HindIII overhangs (Sigma/Aldrich, Poole, UK) and cloned into 
the expression vector pSilencer 3.0-H1 (Life Technologies Ltd., Paisley, UK). All clones 
were purified using an EndoFree Plasmid Maxi Kit (Qiagen Ltd., Crawley, UK) and 
sequenced (Geneservice Ltd., Cambridge, UK). PASMCs were transfected using the Basic 
Nucleofector™ Kit for Primary Mammalian Smooth Muscle Cells and a nucleofector device 
(Nucleofector™ Technology, Lonza, Slough, UK); after 72 hr cells were serum starved for 
24 hr prior to use. Transfection efficiency was >80%, as determined using pmaxGFP (green 
fluorescent protein expressing vector) provided in the kit and confirmed by fluorescence 
microscopy. Efficiency and selectivity of knockdown was confirmed by Western blot. 
Estimation of reactive oxygen species  
As a qualitative, real-time estimation in intact arteries maintained under identical conditions 
to contraction studies, MA were mounted on a confocal wire myograph (Danish Myo 
Technology, Denmark) and pre-conditioned as above. Following incubation with 10 µmol/l 
carboxy 2',7'-dichlorofluorescin-diacetate (C-DCFH/DA) for 45 min at 37C, excess dye was 
washed off and tissue fluorescence of oxidized C-DCF (excitation 490 nm, emission 530 nm) 
recorded every 30s using an inverted microscope (Zeiss UK Ltd) and microfluorimeter 
(Cairn Research Ltd, Faversham, UK). After a stable baseline was established (~30 min), 
SPC was added to the bath.  
ROS generation in cultured cells was estimated using lucigenin-enhanced luminescence. 
PASMCs (passage 4) were cultured to confluence in 24 well plates and growth arrested for 
24 hr. Medium was replaced with gassed PSS at 37C containing 5 µmol/l lucigenin and 100 
µmol/l NADPH, to which SPC and pharmacological inhibitors were added. Luminescence 
was measured at 37C using a Hidex Chameleon plate reader (Hidex,  Finland).  
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Electrophysiology 
Freshly isolated mesenteric artery smooth muscle cells (MASMCs) were obtained from third 
to fourth order MA by enzymatic dispersion, and recordings of whole-cell currents performed 
with patch clamp as described previously 
26
. Ba
2+
 was used as a charge carrier to record 
currents (IBa) through voltage-gated L-type Ca
2+
 channels, with an extracellular solution 
containing (mmol/l): 10 BaCl2, 130 NaCl, 5 CsCl, 1 MgCl2, 5 HEPES, 5 glucose, pH 7.35, 
and a pipette solution containing (mmol/l): 120 Cs methansulphonate, 20 CsCl, 2 MgATP, 
0.5 Na2GTP, 0.3 MgCl2, 5 HEPES, pH 7.2. Cells were equilibrated with pipette solution for 3 
min after whole-cell access before recording the control (time 0) current-voltage (I-V) 
relationship using 120 ms voltage steps between -80 and +80 mV; holding potential was -70 
mV. Cells were then incubated for 5 min with either 200 nmol/l SPC, 1 µmol/l LY83583, or 
in the absence of drug (time control), prior to recording of the test I-V relationship. The effect 
of Tempol (3 mmol/l) was studied on cells pre-incubated for 2 min before addition of 200 
nmol/l SPC.  
Calculations and statistical analysis  
Tension was normalized to the response to KPSS, or for potentiation experiments to the 
control response prior to addition of SPC. Results are expressed as means ± SEM. 
Concentration-response curves were fitted to individual experiments using a Hill equation to 
provide EC50 and fitted maximum (Vmax) (Sigmaplot 12, Systat Software Inc., CA); for 
analysis EC50 was expressed as pD2 (-log EC50). Statistical analysis was performed using 
ANOVA with a Holm-Sidak post hoc unless otherwise stated (Sigmaplot, Systat Software 
Inc., CA). Statistical significance was deemed if p<0.05.   
Reagents 
U73122, Gö6983, Gö6976, PP2 and rottlerin were obtained from Calbiochem, UK;  
C-DCFH/DA from Invitrogen, UK, and all other reagents including PKC translocation 
inhibitor peptide from Sigma-Aldrich, UK. 
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RESULTS 
Potentiation of vasoconstriction by sub-contractile concentrations of SPC  
As previously reported for rat IPA 
10
, 1 µmol/l SPC alone had no effect on tension in rat or 
mouse MA (e.g. Fig 1A, 2A), or rat renal or femoral artery.  
Rat small MA were challenged with sequential 5 min applications of PSS containing ~25 
mmol/l [K
+
] to cause a small depolarization-induced rise in tension of 5.8 +/- 0.6% (n=31) of 
that induced by KPSS, as previously described 
10
. SPC (1 mol/l) was added to the bath, and 
the procedure repeated at 15 min intervals in the continued presence of SPC. SPC strongly 
potentiated the subsequent response to depolarization, and this gradually increased with time 
(Fig. 1A,B), such that at 30 min (2
nd
 challenge post-SPC) force was increased to 512 +/- 40% 
of control (n=31, p<0.001; Fig. 1C). Baseline tension measured immediately before each 
depolarizing challenge was unchanged from control (Fig. 1B), consistent with the lack of 
effect of SPC alone, and in the absence of SPC the response to repeated depolarization was 
also unchanged over 45 min (Fig. 1A). SPC (1 µmol/l) caused the same degree of 
potentiation at 30 min in IPA (to 505 +/- 39% control, n=47, p<0.001) and small renal 
arteries (510 +/- 107% control, n=9, p<0.01) as MA, but had a smaller effect in large femoral 
artery (163 +/- 23%, n=12, p<0.05).  
SPC also potentiated agonist-induced constriction in MA. Preincubation with SPC (1 mol/l) 
caused a substantial leftward shift in the PGF2α cumulative concentration response curve, 
reducing the EC50 from ~20 to ~7 mol/l (pD2: control: 4.78 +/- 0.30, n=5; SPC: 5.29 +/- 
0.14, n=6; p<0.05). We previously reported the same for IPA 
10
. 
Signaling pathways involved in SPC-mediated potentiation 
Arteries were incubated with pharmacological inhibitors for 15 min, and 2 control 
depolarizations were performed before 1 mol/l SPC was added as above. Potentiation at 30 
min (2
nd
 challenge post-SPC) was greatly suppressed or abolished by U73122 (PLC inhibitor, 
10mol/l), Gö6983 (broad spectrum PKC inhibitor, 3 mol/l), and rottlerin (putative PKC 
inhibitor, 1 mol/l, though see below), but not by Gö6976 (inhibitor of conventional but not 
novel PKC isoforms, 3 mol/l) or Y27632 (Rho kinase inhibitor, 3 mol/l) (Fig.1C). The 
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SPC-induced potentiation of depolarization-induced contraction in MA thus exhibited the 
same pharmacological profile as we previously reported for IPA 
10
, suggesting the same 
underlying mechanism. 
Based on the differential effects of Gö6976 and broad spectrum PKC inhibitors, rottlerin and 
PKC translocation studies, we previously suggested that SPC-induced potentiation of IPA 
vasoreactivity involved the novel PKC isoform 10. However, concerns about the specificity 
of rottlerin 
27
 led us to examine this further, and indeed we found no difference between MA 
from WT and PKC-/- mice (Fig. 2A, B).  
The above precludes any role for PKC, suggesting involvement of PKC, another novel 
isoform implicated in the actions of SPC 
28
. We were unable to source PKC-/- mice, but 
utilized instead the specific PKCε translocation inhibitor peptide (Glu-Ala-Val-Ser-Leu-Lys-
Pro-Thr) 
29
. This strongly suppressed SPC-induced potentiation of depolarization-induced 
contraction in both MA and IPA (Fig. 3A, 3B). SPC (1 mol/l) also caused translocation of 
PKCε in cultured PASMCs and MASMCs (Fig. S1, Supplementary data). 
Role of NADPH oxidase and ROS  
Both PKC and Src kinase are known to activate NOX 30-32, and Src has been implicated in 
the actions of SPC in coronary artery 
33
. PP2 (Src inhibitor, 10 mol/l), VAS2870 (novel 
selective inhibitor of NOX, 10 mol/l) 34,35, and Tempol (membrane-permeable catalytic 
superoxide scavenger, 3 mmol/l) all strongly suppressed SPC-induced potentiation of 
depolarization-induced contraction in both rat MA and IPA (Fig. 3A, 3B). Similarly, 
application of Tempol on top of an established constriction reversed SPC-induced 
potentiation by 95 +/- 12 % (p<0.01; n=4) in MA (Fig. 3C).  
To determine the NOX isoform, we used the same protocol but with MA from mice lacking 
gp91
phox
 (NOX2) or p47
phox
, the organizer sub-unit for NOX2 and NOX1. Whilst potentiation 
was the same in MA from WT and gp91
phox-/-
 mice, it was absent in mice lacking p47
phox
 
(Fig. 2A, 2B). This strongly suggests that activation of NOX1 and consequent generation of 
ROS are essential for the potentiating actions of SPC.  
We examined whether ROS were also responsible for SPC-induced potentiation of agonist-
induced contraction. We utilized U46619, as unlike PGF2α it only activates TP receptors; 
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experiments were performed in the presence of 100 mol/l L-NAME to mitigate against any 
complicating effects of NO. U46619 concentration-response curves are repeatable; three were 
performed on each MA: control, following incubation with SPC (1 mol/l), and SPC plus 
Tempol (3mmol/l). A separate set of time matched experiments were performed with Tempol 
alone. SPC caused a large left-ward shift in the U46619 concentration-response relationship 
(p<0.001), which was ablated in the presence of Tempol such that the relationship was 
shifted significantly to the right of control (p<0.05) (Fig. 4A). There was no difference 
between the effects of SPC plus Tempol and Tempol alone.  
To determine the mechanism by which SPC potentiates U46619-induced contraction, we 
performed similar experiments using nifedipine (3μmol/l; L-type channel blocker). 
Nifedipine suppressed the response to U46619 (Fig 4B), and in its presence SPC was without 
any effect. This suggests SPC potentiates U46619-induced contraction by enhancing voltage 
gated Ca
2+
 entry.  
As Tempol suppressed the effects of sub-contractile concentrations of SPC, we examined 
whether it would also suppress the effects of higher concentrations of SPC which do elicit 
vasoconstriction. Indeed, Tempol suppressed SPC-induced contraction in MA by ~75% 
(p<0.001; Fig. 4C). Conversely nifedipine only reduced the response to SPC by ~50%, as 
expected because SPC >~5 μmol/l also activates Rho kinase mediated Ca2+ sensitization 1,5-9. 
These results imply that SPC-induced contraction in MA is largely mediated via ROS.  
Does SPC increase ROS generation? 
As a qualitative measure of ROS production we examined the effect of SPC on C-DCFH 
oxidation in intact, unstimulated MA mounted on a myograph. SPC increased the rate of C-
DCFH oxidation in a concentration dependent manner, under identical conditions to those 
used for contraction studies (Fig. 5A).          
Addition of SPC (1 mol/l) caused a ~40% increase in lucigenin-enhanced luminescence in 
unstimulated cultured PASMCs (n=11, p<0.001), which was effectively abolished by 
preincubation with Gö6983 (3 mol/l), PP2 (10 mol/l) and VAS2870 (10 mol/l) such that 
there was no significant elevation above basal luminescence (Fig. 5B); none of these agents 
alone had any effect on basal luminescence. 10 mol/l SPC had a significantly stronger effect 
(~80% increase, n=12, p<0.001, 10 mol/l vs 1 mol/l SPC). However, whilst VAS2870 still 
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strongly suppressed the response to 10 mol/l SPC, Gö6983 and PP2 were only partially 
effective at this concentration (Fig. 5B).  
In order to confirm a role for PKC upstream of ROS generation, and to positively identify 
the PKC isoform, we transfected cells with siRNA against PKC or PKC, or scrambled 
siRNA. PKC siRNA reduced protein expression to 19.7 +/- 2.6% of control, and strongly 
suppressed the increase in lucigenin luminescence induced by 1 and 10 mol/l SPC (n=5, 
p<0.001 for both). PKC siRNA reduced protein expression to 20.5 +/- 1.3%, but had no 
effect on SPC-induced luminescence (n=4; Fig. 5C). Neither siRNA had a significant 
influence on basal luminescence.   
Do exogenous ROS mimic the effects of SPC? 
The above results suggest that SPC-induced potentiation of vasoreactivity is mediated via a 
PLC-, PKC- and Src-dependent activation of NOX1, and consequent generation of ROS. 
We therefore examined whether exogenous ROS could mimic the effects of SPC using 
LY83583, a membrane permeable quinolinequinone that acts within the cell to generate 
intracellular superoxide 
20,36
. At 1 µmol/l LY83583 does not itself alter vascular tension 
20,36
 
(and see Fig. 6A), but like SPC it substantially enhanced the response to depolarization with 
~25 mmol/l [K
+
] in both MA and IPA (Fig. 6A and B; p<0.001). In contrast to SPC, however, 
the effects were not significantly inhibited by Gö6983, PP2 or VAS2870 (Fig. 6B), consistent 
with ROS being downstream of PKC- and Src-mediated activation of NOX1. 
SPC potentiation of voltage-gated Ca
2+
 channels 
We examined the effects of SPC on voltage-gated Ca
2+
 currents using whole cell patch clamp 
and Ba
2+
 as a charge carrier, in freshly isolated myocytes from rat MA (Fig. 7). We utilized 
200 nmol/l SPC because 1 µmol/l caused rapid loss of attachment. To account for current 
run-down, comparisons were made between different cells 5 min after addition of SPC or 
solvent (PSS). SPC (200 nmol/l) increased peak current at 5 min to 176 +/- 17% (n=7; 
p<0.01) of that in control cells, and this enhancement was abolished in presence of 3 mmol/l 
Tempol (90 +/- 13%, n=6; p<0.01 vs SPC alone, NS vs control; Fig. 7). As predicted, the 
intracellular ROS generator LY83583 (1 µmol/l) had a similar effect to that of SPC (145 +/- 
12%, n=6; p<0.05). 
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DISCUSSION 
We previously reported that concentrations of SPC  1 μmol/l, insufficient to elicit elevation 
of [Ca
2+
]i or vasoconstriction alone, nevertheless strongly potentiate depolarization- and 
agonist-induced constriction of small IPA by enhancing Ca
2+
 entry 
10
. The precise mechanism 
however remained unclear, and it was unknown whether this phenomenon was limited to 
pulmonary arteries, which have unique responses to hypoxia and some other stimuli 
20,21,37
. 
The key findings of the present study are that such concentrations of SPC also strongly 
potentiate vasoreactivity of small MA and renal arteries, and that for both MA and IPA this is 
mediated via an increase in ROS generated by NOX1 and enhancement of Ca
2+
 entry through 
L-type channels.  
SPC (1 μmol/l) enhanced constriction induced by mild depolarization with ~25 mmol/l [K+] 
by the same extent (~400% at 30 min) in small IPA, MA and renal arteries, but to a lesser 
degree in large femoral artery (~60%). The latter may reflect the suggestion that SPC plays a 
greater role in distal compared to large proximal arteries 
38
. The relatively slow onset, with 
maximum effect around 50-60 min (Fig.1B), was similar in all artery types and to 
vasoconstriction induced by high (e.g. 10 μmol/l) concentrations of SPC 9,33. Whilst this 
could reflect accumulation of SPC in the membrane or of a secondary mediator, it is 
noticeable that there was no increase in basal tension over at least 45 min (Fig. 1B). As we 
previously reported for IPA 
10,20, preincubation with 1 μmol/l SPC also potentiated the 
response of MA to PGF2α and U46619, demonstrated here by a large shift to the left of the 
concentration-response curve (Section 3.1 and Fig. 4A).  
SPC-induced potentiation of vasoreactivity in rat MA exhibited the same pharmacological 
profile as we reported for IPA 
10
 (Fig. 1C), as it was abolished by the PLC inhibitor U73122 
and the putative PKC inhibitor rottlerin (but see below), and strongly suppressed by Gö6983 
(inhibitor of conventional and novel PKCs), but not by Gö6976 (conventional PKCs only) 
nor the Rho kinase inhibitor Y27632. PLC has previously been established as a critical 
component of SPC signaling, and at higher concentrations (>5 μmol/l) SPC strongly activates 
Rho kinase and Ca
2+
 sensitization in many vascular beds 
1,5,6,9,39
, though the latter is clearly 
not involved at low concentrations.  
The differential effects of Gö6983 and Gö6976 imply a novel isoform of PKC 
29
, which like 
conventional PKCs are activated by PLC-derived diacylglycerol; conventional PKCs have 
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been previously shown to play no role in the action of SPC 
6,28
. Whilst we originally 
proposed PKC, we show here that SPC-induced potentiation of constriction was unaltered in 
MA from mice lacking PKCδ (Fig. 2). However another novel isoform, PKC, has been 
implicated in SPC-induced constriction of cat oesophagus smooth muscle 
28
. Consistent with 
this, the specific PKC inhibitory peptide strongly inhibited SPC-induced potentiation in both 
IPA and MA (Fig. 3A and B).  
SPC increases ROS generation in keratinocytes, endothelial and Jurkat cells (albeit all at 10 
μmol/l), most likely via NOX 11-14, and PKCis known to activate NOX in cardiac 31 and 
pulmonary artery myocytes 
40
. Both PKC and Src phosphorylate the p47
phox
 organiser sub-
unit of NOX1 and NOX2, essential for translocation of cytosolic sub-units and activation of 
the oxidase complex 
32
. Interestingly, Src and PKC are themselves redox sensitive, giving 
rise to the possibility of positive feedback mediated amplification 
40,41
. Consistent with a 
central role for NOX-generated ROS, SPC-induced potentiation of depolarization-induced 
constriction was strongly suppressed in both MA and IPA by the novel NOX inhibitor 
VAS2870 
34,35
, Src inhibitor PP2, and superoxide scavenger Tempol (Fig. 3). Tempol also 
reversed the potentiation by SPC of U46619-induced vasoconstriction (Fig. 4A). Moreover, 
the potentiating effect of SPC was abolished in MA from p47
phox -/-
 but not gp91
phox -/-
 mice 
(Fig. 2); this strongly implicates NOX1 as the relevant isoform, as only NOX1 and NOX2 
require p47
phox
.  
Consistent with the above, 1 μmol/l SPC increased ROS generation both in intact MA and 
cultured vascular smooth muscle cells, an action effectively abolished in the latter by 
Gö6983, PP2 and VAS2870, and also following siRNA knockdown of PKC (but not PKC) 
(Fig. 5). Furthermore, sub-contractile concentrations of the intracellular superoxide generator 
LY83583 mimicked the actions of SPC (Fig. 6), and we have previously shown that such 
concentrations also enhance agonist-induced contraction in MA and IPA 
20
. Inhibition of 
PKC or Src did not affect LY83583-induced potentiation (Fig. 6), suggesting that in these 
circumstances PKC and Src play a primarily upstream role to generation of ROS. These 
results strongly suggest that the effects of SPC reported here are mediated by increased 
generation of NOX1-derived ROS. 
Concerning the mechanism by which low concentrations of SPC enhance vascular reactivity, 
our current and previous 
10
 results exclude any role for a Rho kinase- (or PKC) mediated 
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increase in Ca
2+
 sensitivity, although at higher concentrations both SPC and ROS do activate 
Rho kinase 
6,9,20,39
. However, voltage-dependent Ca
2+
 entry induced by depolarization or 
agonist was increased 
10
. Whilst this might occur if SPC induced some depolarization itself, 
and NOX-derived ROS have been reported to inhibit Kv channels in pulmonary artery 
40,42
, 
SPC did not suppress KV currents in IPA, and indeed still potentiated the response in 
maximally depolarized arteries 
10
. Moreover, we have reported that intracellularly generated 
ROS cause a negative shift in the activation of KV current in both MA and IPA, which would 
tend to have a hyperpolarizing effect 
20
.  
ROS and redox state are known to affect the function of L-type Ca
2+
 channels, the α1C 
subunit of which contains multiple redox-sensitive cysteine residues 
15
, and NOX-derived 
ROS are reported to enhance L-type Ca
2+
 channel currents in both cardiac and vascular 
smooth muscle 
16-19
. Consistent with this, we found that 200nmol/l SPC potentiated L-type 
Ca
2+
 channel current (Ba
2+
 as charge carrier) in MA smooth muscle cells, and this was 
prevented by Tempol and mimicked by the superoxide generator LY83583 (Fig. 7).   
Our results are consistent with a model where sub-contractile concentrations of SPC activate 
NOX1 through a PLC, PKC and Src dependent mechanism, and the consequent increased 
generation of ROS enhances Ca
2+
 entry through L-type channels, when these are activated by 
other means. The pathway is apparently identical in MA and IPA. This mechanism may not 
be limited to SPC, as a similar pathway, albeit at concentrations sufficient to cause 
constriction alone, has been proposed for the archetypical NOX activator angiotensin II in 
cerebral arteries 
16
, endothelin 1 in cardiac myocytes 
19
, and U46619 in pulmonary artery 
17,42
. 
Notably, Tempol caused a shift to the right of the control U46619 concentration-response 
curve in MA (Fig. 4A). Whilst these reports may differ in terms of specific isoforms of PKC 
and NOX, and in pulmonary artery the possible involvement of KV channels, the underlying 
signaling pathway is very similar. Note however that all these studies utilized agonist 
concentrations that in themselves cause constriction and activation of parallel Ca
2+
 
mobilization and other pathways, which might underlie reported differences.     
Considering the above, we briefly examined whether ROS and NOX signaling was important 
for constriction elicited by higher concentrations of SPC, which has been attributed to 
activation of voltage dependent and independent Ca
2+
 entry and Rho kinase-mediated Ca
2+
 
sensitization 
1,6-9
. Notably, all of these have been reported to be activated by ROS 
32,41
. We 
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found that Tempol suppressed SPC-induced constriction by >80% in MA (Fig. 4B), and that 
10 μmol/l SPC doubled the rate of ROS generation compared to 1 μmol/l (Fig. 5B). Whilst 
this implies that ROS form a key signaling component for SPC at any concentration, the fact 
that Gö6983, PP2 and knockdown of PKC only partially inhibited the elevation of ROS 
elicited by 10 μmol/l SPC suggests that an additional pathway may be activated by 
concentrations >1 μmol/l, as previously suggested for other cell types 43.   
Conclusion 
We demonstrate here that low concentrations of SPC, insufficient to elicit vasoconstriction 
alone, strongly potentiate vasoreactivity via PLC, PKC and Src dependent activation of 
NOX1, increased generation of ROS, and consequent enhancement of Ca
2+
 entry through L-
type channels. SPC has been implicated in cardiovascular disease, though the majority of in 
vitro studies utilized concentrations probably well in excess of physiological levels 
1-3
. The 
concentrations used here and previously (≤1 μmol/l) 10 are closer to those reported in plasma 
44
, although physiologically relevant concentrations at the cell surface are difficult to 
determine because of autocrine and paracrine production, and extensive binding to albumin, 
HDLs and LDLs 
1,4,12
. Nevertheless, our results suggest that physiological or 
pathophysiological concentrations of SPC could greatly increase vascular reactivity to other 
stimuli. In addition, we can speculate from the data shown in Fig. 4B that many of the 
vascular actions of SPC might be mediated via increased ROS. In this respect there are 
similarities between SPC and angiotensin II, which share many downstream pathways 
1,45
.  
The question arises as to why SPC and low concentrations of ROS should have similar 
effects in MA and IPA 
4,5,9,20
, whereas higher concentrations of exogenous ROS are reported 
to constrict pulmonary but relax systemic arteries 
20,21,40
. It is probable that this relates to 
compartmentalization of SPC-induced ROS signaling, synonymous to that for Ca
2+
. Notably, 
angiotensin II causes highly localized sub-plasmalemmal generation of ROS and co-localized 
L-type channel activity in cerebral artery, suggesting clustering of receptors, NOX and L-type 
channels in a micro-signaling domain 
16
. We speculate that a similar situation exists for SPC 
and an as yet unidentified high affinity SPC receptor. Higher concentrations of exogenous 
ROS would however have more promiscuous effects, for example relaxing MA (but not IPA) 
by opening Kv channels 
20
, and constricting IPA (but not MA) in part by mobilizing 
ryanodine-sensitive Ca
2+
 stores 
21,30
.  
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In summary, we present evidence for a novel pathway by which physiological concentrations 
of SPC strongly potentiate vasoreactivity, involving PLC, NOX1 and ROS-mediated 
enhancement of voltage gated Ca
2+
 entry. Similarities with other studies suggest that this 
could potentially be common to other GqPCR and PLC-coupled agonists, with significant 
implications for vascular regulation and disease. 
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Figure legends 
Figure 1 - SPC-induced potentiation of tension development in MA 
Panel A: Typical recordings of tension developed in rat MA to 5 min challenges with PSS 
containing 25 mmol/l [K
+
], demonstrating strong potentiation of contraction following 
addition of 1 μmol/l SPC compared to time control.  
Panel B: Mean data from 31 MA (24 rats). Open symbols represent increase in tension over 
control response (challenge 0 at time 0, i.e. 0/0) following addition of SPC. Filled symbols 
represent tension immediately preceding each depolarising challenge, demonstrating a stable 
baseline. Bars = SEM, where not shown, smaller than symbol. ** p<0.001 vs control; RM 
ANOVA on ranks, Tukey post hoc. 
Panel C: SPC-induced potentiation in MA from 24 rats at 30 min (challenge 2) in the 
presence of U73122 (PLC inhibitor, n=4), Go6976 (conventional PKC inhibitor, n=7), 
Go6983 (broad spectrum PKC inhibitor, n=6), rottlerin (putative PKC inhibitor, n=5) and 
Y27362 (Rho kinase inhibitor, n=7). Bars = SEM. ** p<0.001 vs SPC alone; †† p<0.001 vs 
control;  2 way ANOVA, Holm-Sidak post hoc.   
Figure 2 - SPC-induced potentiation in MA of GM mice 
We found no difference between MA from C57BL/6 and 129/SV WT mice, so the data were 
pooled.  
Panel A: Typical tension recordings from MA of WT, PKC-/-, gp92phox-/- and p47phox-/- mice 
for 5 min challenges with PSS containing 25 mmol/l [K
+
] in the presence of 1 μmol/l SPC. 
Panel B: Mean data from WT (n=11, 7 mice), PKC-/- (n=4, 4 mice), gp92phox-/- (n=6, 4 mice) 
and p47
phox-/-
 (n=11, 7 mice) (challenge 2). Bars = SEM. †† p<0.001 vs control;  2 way 
ANOVA, Holm-Sidak post hoc.     
Figure 3 – Effects of inhibitors on  SPC-induced potentiation in MA and IPA 
Panel A: SPC-induced potentiation (challenge 2) of MA for SPC alone (n=31, 24 rats), and in 
the presence of PKC peptide inhibitor (n=6), PP2 (Src inhibitor, n=7), Tempol (n=11, 8 rats) 
and VAS2870 (NOX inhibitor, n=4); 24 rats. 
Panel B: SPC-induced potentiation (challenge 2) of IPA for SPC alone (n=47, 30 rats), and in 
the presence of PKC peptide inhibitor (n=8), PP2 (n=8), Tempol (n=11) and VAS2870 
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(n=4); 20 rats.  
Panel C: Typical trace showing reversal of SPC-induced potentiation in an MA by addition of 
Tempol (3 mmol/l).  
Bars = SEM. ** p<0.001 vs SPC alone;  2 way ANOVA, Holm-Sidak post hoc. 
Figure 4 – U46619 and SPC-induced contraction, and effects of Tempol    
Panel A: Cumulative concentration-response curves for U46619: control (filled circle), SPC 
(1 μmol/l; open circle), SPC + Tempol (open square); 12 MA (6 rats). Tempol alone (filled 
square); n=8 MA (4 rats). Mean pD2: Control: 7.11 +/- 0.02; SPC: 7.53 +/- 0.03, p<0.001 vs 
control; SPC + Tempol: 6.99 +/- 0.02, p<0.001 vs SPC, p<0.02 vs control; RM ANOVA, 
Holm-Sidak post hoc. pD2 for Tempol alone: 6.90 +/- 0.08, NS vs Tempol + SPC; p<0.05 vs 
Control; 1 way ANOVA , Holm-Sidak post hoc. Bars = SEM. 
Panel B: Similar to panel A, but in the presence of nifedipine (3 μmol/l; open square), and 
SPC + nifedipine; filled square); 15 MA (9 rats). Control: pD2: 7.04 +/- 0.06, Vmax: 144 +/- 
13% KPSS; nifedipine: pD2: 6.64 +/- 0.05, p<0.001 vs control, Vmax: 43 +/- 5% KPSS, 
p<0.001 vs control; SPC + nifedipine: pD2: 6.67 +/- 0.03, NS vs nifedipine alone, Vmax: 53 
+/- 6% KPSS, NS vs nifedipine alone; RM ANOVA, Holm-Sidak post hoc.  
Panel C: Cumulative concentration-response curves for SPC in MA (filled circles); 16 MA 
(10 rats), with Tempol (filled squares); 8 MA (5 rats), or nifedipine (open squares); 10 MA (6 
rats). SPC: pD2: 5.08 +/- 0.04, Vmax: 16.8 +/- 1.3% KPSS; SPC + Tempol: pD2: 4.84 +/- 
0.06, p<0.02 vs control, Vmax: 4.24 +/- 1.2% KPSS, p<0.001 vs control; SPC + nifedipine: 
pD2: 5.10 +/- 0.06, NS vs control, Vmax: 8.25 +/- 1.1% KPSS, p<0.002 vs control, p<0.05 vs 
Tempol; 1 way ANOVA, Holm-Sidak post hoc. Bars = SEM (not shown if smaller than 
symbol).   
Figure 5 – Effect of SPC on ROS generation 
Panel A: Mean of real-time recordings from intact MA from 3 rats showing increased 
oxidation of C-DCFH (fluorescence at 530 nm) following addition of SPC. Data normalised 
to initial fluorescence; bars = SEM, shown at 2 min intervals for clarity. 
Panel B: Increase in lucigenin luminescence in PASMCs cultured from 8 rats following 
addition of 1 (n=11) or 10 (n=12) μmol/l SPC, and in the presence of Gö6983 (n=6 and 7), 
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PP2 (n=9 and 11) and VAS2870 (n= 4 and 4). † <0.01, †† p<0.001 vs control (no SPC);  ** 
p<0.001 vs 1 μmol/l SPC alone; # p<0.05, ## p<0.001 vs 10 μmol/l SPC alone; 1 way 
ANOVA, Holm-Sidak post hoc. Bars = SEM. 
Panel C: Increase in lucigenin luminescence following addition of 1 or 10 μmol/l SPC in 
PASMCs (cultured from 6 rats) transfected with scrambled siRNA (n=12), PKC siRNA 
(n=4) or PKC siRNA (n=5).  † <0.01, †† p<0.001 vs control (no SPC); ** and ## p<0.001 
vs scrambled siRNA with 1 or 10 μmol/l SPC; 1 way ANOVA, Holm-Sidak post hoc. Bars = 
SEM. 
Figure 6 – The ROS generator LY83583 mimics effect of SPC  
Panel A: Typical tension recordings from rat MA and IPA for 5 min challenges with PSS 
containing ~25 mmol/l [K
+] and following addition of 1 μmol/l LY83583, showing 
potentiation of the response.  
Panel B: LY83583 (LY)-induced potentiation at 30 min in 9 MA (5 rats) and 9 IPA (5 rats),  
and in the presence of Go6983 (Go, 4 MA, 4 IPA), PP2 (11 MA, 8 IPA) and VAS2870 
(VAS, 6 MA); 18 rats. Bars = SEM. †† p<0.001 vs control (no LY83583); no inhibitor had 
any significant effect; 1 way ANOVA, Holm-Sidak post hoc. 
Figure 7 – Voltage-gated calcium currents and SPC 
Panel A: Representative whole cell IBa currents following step to +20 mV from holding 
voltage from 4 freshly isolated MA myocytes (cell capacitance shown). Grey lines show 
current immediately following patching (0 min) and before addition of agent; black lines 
current 5 min later and in the presence of agent. Note current rundown in control trace.  
Panel B: I-V plots of IBa densities for MA myocytes from 14 rats (control, closed circles, 
n=11), in the presence of 200 nmol/l SPC (open circles, n=7), and in the combined presence 
of SPC and 3 mmol/l Tempol (n=6). Further details in Methods. Bars = SEM. 
Panel C: Percentage change in peak IBa at 5 min relative to the initial control current at time 0 
derived from data above. Time control showing typical IBa rundown, n=11; SPC, n=7; 
SPC+Tempol, n=6; LY83583 (1 μmol/l), n=6). Bars = SEM. * p<0.05; ** p<0.001 vs time 
control; # p<0.05 vs SPC alone; 1 way ANOVA, Holm-Sidak post hoc.   
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